Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Change in Inventory (2019 - 2025)

Historic Change in Inventory for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $782000.0.

  • Harmony Biosciences Holdings' Change in Inventory fell 3852.2% to $782000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$33000.0, marking a year-over-year decrease of 10180.53%. This contributed to the annual value of $1.8 million for FY2024, which is 7213.88% up from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Change in Inventory stood at $782000.0, which was down 3852.2% from -$284000.0 recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year Change in Inventory high stood at $1.3 million for Q3 2024, and its period low was -$814000.0 during Q1 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' median Change in Inventory value was $233000.0 (recorded in 2023), while the average stood at $161000.0.
  • Its Change in Inventory has fluctuated over the past 5 years, first soared by 44592.27% in 2024, then tumbled by 26477.73% in 2025.
  • Harmony Biosciences Holdings' Change in Inventory (Quarter) stood at -$373000.0 in 2021, then soared by 206.43% to $397000.0 in 2022, then tumbled by 30.48% to $276000.0 in 2023, then increased by 2.54% to $283000.0 in 2024, then skyrocketed by 176.33% to $782000.0 in 2025.
  • Its Change in Inventory was $782000.0 in Q3 2025, compared to -$284000.0 in Q2 2025 and -$814000.0 in Q1 2025.